Scotts Miracle-Gro (SMG), unlike Canopy Growth (WEED), Cronos Group (CRON), and Aurora Cannabis (ACB) (ACBFF), isn’t a licensed cannabis producer (HMMJ). However, it supplies products that support the cultivation of cannabis. The company primarily serves the North American market with lawn and garden products such as fertilizers, pesticides, and seeds.
The mean consensus rating for Scotts Miracle-Gro as of April 12, 2018, is 2.3, which is the same as March. The consensus mean recommendation for the stock is a “buy” for the next 12-month period.
In the above chart, you can see that analysts’ recommendations haven’t changed month-over-month. Two analysts are maintaining a “strong buy” recommendation, two are maintaining a “buy” recommendation, and five are maintaining a “hold.”
While the current ratings on SMG stock are unchanged, its current mean price target has fallen from $102 in March to $100.80 in April. Its median price target also fell from $100 to $97.50. The stock closed at $82.50 on April 12, 2018, giving it a potential upside of 22% over its mean price target and 18% over its median price target.
You may also be interested in reading Key Takeaways from Hydropothecary’s Fiscal 2Q18 Earnings.